Varicose Veins Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major varicose veins markets are expected to exhibit a CAGR of 5.3% during 2024-2034.
The varicose veins market has been comprehensively analyzed in IMARC's new report titled "Varicose Veins Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Varicose veins refer to a common condition characterized by enlarged, twisted, and swollen veins that usually appear on the legs and feet. These veins can be blue, purple, or red in color and are often visible through the skin. Some of the associated symptoms are bulging veins on the legs, dark purple or blue discoloration of the veins, aching or throbbing pain in the legs, a feeling of heaviness in the legs, swelling in the ankles and feet, itching or irritation around the affected veins, cramping or restless legs, etc. In many instances, varicose veins can lead to various complications, such as skin changes like dryness, thickening, inflammation, ulcers or sores, etc. The diagnosis of the condition typically involves a combination of medical history assessment, physical examination, and diagnostic tests. A physical exam may include inspecting and palpating the affected areas to identify the appearance of varicose veins, check for signs of complications, and evaluate blood flow. Various diagnostic procedures, such as Doppler ultrasound, may be performed to determine the functioning of the veins and locate any underlying vein abnormalities or blood clots.
The increasing cases of weakened or damaged valves within the veins, which disrupt the normal flow of blood, are primarily driving the varicose veins market. Furthermore, the rising prevalence of numerous associated risk factors, such as hormonal fluctuations, pregnancy, genetic predisposition, advancing age, prolonged sitting or standing, prior vein damage, etc., is creating a positive outlook for the market. Apart from this, the widespread adoption of sclerotherapy, which involves injecting a sclerosing solution directly into the affected veins, causing them to collapse and fade over time, is also bolstering the market growth. Moreover, the escalating utilization of compression stockings, since they help in promoting blood flow, thereby pushing the blood upwards towards the heart and reducing the pooling of blood in the veins, is acting as another significant growth-inducing factor. Additionally, the inflating application of endovenous thermal ablation on account of its several associated benefits, such as less post-procedural pain, decreased scarring, and a faster recovery compared to traditional surgical procedures like vein stripping, is expected to drive the varicose veins market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the varicose veins market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for varicose veins and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the varicose veins market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the varicose veins market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the varicose veins market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current varicose veins marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the varicose veins market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the varicose veins market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the varicose veins market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of varicose veins across the seven major markets?
What is the number of prevalent cases (2018-2034) of varicose veins by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of varicose veins by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with varicose veins across the seven major markets?
What is the size of the varicose veins patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of varicose veins?
What will be the growth rate of patients across the seven major markets?
Varicose Veins: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for varicose veins drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the varicose veins market?
What are the key regulatory events related to the varicose veins market?
What is the structure of clinical trial landscape by status related to the varicose veins market?
What is the structure of clinical trial landscape by phase related to the varicose veins market?
What is the structure of clinical trial landscape by route of administration related to the varicose veins market?
The varicose veins market has been comprehensively analyzed in IMARC's new report titled "Varicose Veins Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Varicose veins refer to a common condition characterized by enlarged, twisted, and swollen veins that usually appear on the legs and feet. These veins can be blue, purple, or red in color and are often visible through the skin. Some of the associated symptoms are bulging veins on the legs, dark purple or blue discoloration of the veins, aching or throbbing pain in the legs, a feeling of heaviness in the legs, swelling in the ankles and feet, itching or irritation around the affected veins, cramping or restless legs, etc. In many instances, varicose veins can lead to various complications, such as skin changes like dryness, thickening, inflammation, ulcers or sores, etc. The diagnosis of the condition typically involves a combination of medical history assessment, physical examination, and diagnostic tests. A physical exam may include inspecting and palpating the affected areas to identify the appearance of varicose veins, check for signs of complications, and evaluate blood flow. Various diagnostic procedures, such as Doppler ultrasound, may be performed to determine the functioning of the veins and locate any underlying vein abnormalities or blood clots.
The increasing cases of weakened or damaged valves within the veins, which disrupt the normal flow of blood, are primarily driving the varicose veins market. Furthermore, the rising prevalence of numerous associated risk factors, such as hormonal fluctuations, pregnancy, genetic predisposition, advancing age, prolonged sitting or standing, prior vein damage, etc., is creating a positive outlook for the market. Apart from this, the widespread adoption of sclerotherapy, which involves injecting a sclerosing solution directly into the affected veins, causing them to collapse and fade over time, is also bolstering the market growth. Moreover, the escalating utilization of compression stockings, since they help in promoting blood flow, thereby pushing the blood upwards towards the heart and reducing the pooling of blood in the veins, is acting as another significant growth-inducing factor. Additionally, the inflating application of endovenous thermal ablation on account of its several associated benefits, such as less post-procedural pain, decreased scarring, and a faster recovery compared to traditional surgical procedures like vein stripping, is expected to drive the varicose veins market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the varicose veins market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for varicose veins and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the varicose veins market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the varicose veins market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the varicose veins market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current varicose veins marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the varicose veins market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the varicose veins market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the varicose veins market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of varicose veins across the seven major markets?
What is the number of prevalent cases (2018-2034) of varicose veins by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of varicose veins by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with varicose veins across the seven major markets?
What is the size of the varicose veins patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of varicose veins?
What will be the growth rate of patients across the seven major markets?
Varicose Veins: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for varicose veins drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the varicose veins market?
What are the key regulatory events related to the varicose veins market?
What is the structure of clinical trial landscape by status related to the varicose veins market?
What is the structure of clinical trial landscape by phase related to the varicose veins market?
What is the structure of clinical trial landscape by route of administration related to the varicose veins market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VARICOSE VEINS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VARICOSE VEINS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VARICOSE VEINS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 VARICOSE VEINS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VARICOSE VEINS - UNMET NEEDS
10 VARICOSE VEINS - KEY ENDPOINTS OF TREATMENT
11 VARICOSE VEINS - MARKETED PRODUCTS
11.1 List of Varicose Veins Marketed Drugs Across the Top 7 Markets
11.1.1 Varithena (Polidocanol) - BTG
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Asclera (Polidocanol) - BioForm Medical/Chemische Fabrik Kreussler & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VARICOSE VEINS - PIPELINE DRUGS
12.1 List of Varicose Veins Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VARICOSE VEINS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VARICOSE VEINS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VARICOSE VEINS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Varicose Veins - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Varicose Veins - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Varicose Veins - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Varicose Veins - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Varicose Veins - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Varicose Veins - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Varicose Veins - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Varicose Veins - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Varicose Veins - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Varicose Veins - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Varicose Veins - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Varicose Veins - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Varicose Veins - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Varicose Veins - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Varicose Veins - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Varicose Veins - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Varicose Veins - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Varicose Veins - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Varicose Veins - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Varicose Veins - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Varicose Veins - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Varicose Veins - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Varicose Veins - Access and Reimbursement Overview
16 VARICOSE VEINS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VARICOSE VEINS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VARICOSE VEINS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VARICOSE VEINS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VARICOSE VEINS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VARICOSE VEINS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 VARICOSE VEINS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VARICOSE VEINS - UNMET NEEDS
10 VARICOSE VEINS - KEY ENDPOINTS OF TREATMENT
11 VARICOSE VEINS - MARKETED PRODUCTS
11.1 List of Varicose Veins Marketed Drugs Across the Top 7 Markets
11.1.1 Varithena (Polidocanol) - BTG
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Asclera (Polidocanol) - BioForm Medical/Chemische Fabrik Kreussler & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VARICOSE VEINS - PIPELINE DRUGS
12.1 List of Varicose Veins Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VARICOSE VEINS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VARICOSE VEINS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VARICOSE VEINS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Varicose Veins - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Varicose Veins - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Varicose Veins - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Varicose Veins - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Varicose Veins - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Varicose Veins - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Varicose Veins - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Varicose Veins - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Varicose Veins - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Varicose Veins - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Varicose Veins - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Varicose Veins - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Varicose Veins - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Varicose Veins - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Varicose Veins - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Varicose Veins - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Varicose Veins - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Varicose Veins - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Varicose Veins - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Varicose Veins - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Varicose Veins - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Varicose Veins - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Varicose Veins - Access and Reimbursement Overview
16 VARICOSE VEINS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VARICOSE VEINS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VARICOSE VEINS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
